We fight to improve the lives
of everyone affected by epilepsy

Warning message

This article was published in November 2011. The information may be out of date. Please check our epilepsy information or our site A-Z.

‘GP’ magazine: retigabine availability

28 Nov 2011

An investigation carried out by ‘GP’ magazine has found that retigabine has been ‘black listed’ by one primary care trust. This is Lincolnshire Prescribing and Clinical Effectiveness Forum (part of NHS Lincolnshire primary care trust).

You can read about the investigation on the ‘GP’ magazine website, here. http://www.gponline.com/News/article/1105156/Exclusive-PCTs-blacklist-dr... 

Retigabine, also known as Trobalt, is a new anti-epileptic drug, which was approved by the National Institute for Health and Clinical Excellence (NICE) as an add-on treatment for focal seizures in July 2011.

As one of its roles, NICE looks at medications and decides whether they are clinically and cost effective. Three months after a drug has been approved by NICE, it should be made available throughout England and Wales.

However, the investigation found that one primary care trust has placed retigabine on a list of drugs that can not be offered, even if a clinician believes a patient may benefit.

Epilepsy Action will be contacting Lincolnshire Prescribing and Clinical Effectiveness Forum to ask why retigabine is not available to treat people with epilepsy in Lincolnshire, and to ask when they intend to make it available.

If people with epilepsy are being denied any anti-epileptic drug, that their clinician believes they should receive, we would like to hear about it. You can contact campaigns@epilepsy.org.uk or telephone 0113 210 8800.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
14 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.